Muraglitazar

Overview

Muraglitazar (BMS-298585) is an orally active non-thiazolidinedione oxybenzylglycine dual-target PPARα / PPARγ agonist, with an IC 50 of 0.25 μM and an EC 50 of 0.32 μM against human PPARα , and an IC 50 of 0.19 μM and an EC 50 of 0.11 μM against human PPARγ . Muraglitazar regulates lipid homeostasis, enhances peripheral insulin sensitivity, and improves β-cell function. Muraglitazar reduces levels of blood glucose, insulin , triglycerides and free fatty acids, normalizes adiponectin and corticosterone levels, promotes cholesterol efflux, reduces hepatic lipid content, regulates body weight, prevents hyperglycemia, and improves glucose tolerance. Muraglitazar can be used in research related to type 2 diabetes and dyslipidemia.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Autoimmune Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > PPAR

Product Information

• Catalog No.: HY-17445
• CAS No.: 331741-94-7
• Molecular Formula: C29H28N2O7
• Molecular Weight: 516.54
• Purity: 98.38%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution
• Availability: In-stock

Source

Original product source